Affilogic is a privately-owned biotech company specialized in discovery and development of a novel class of affinity proteins called Nanofitins®. They are potent antibody-mimetics, exhibiting high affinity and specificity for capture and targeting of biomolecules. Nanofitins® also demonstrate many small molecule-like attributes such as a very small size (7 kDa, around 20 times smaller than a monoclonal antibody), an extreme robustness and better tissue penetration. Deriving from a naturally hyperstable scaffold, Nanofitins® are resistant to temperature and pH, stable to proteases, spontaneously refolding… Being under a single protein format, Nanofitins® are produced by simple, scaleable, GMP-compliant bacterial fermentation at very attractive costs or by chemical synthesis.

Affilogic has designed Nanofitins® against 40+ targets to date, including a wide range of circulating antigens (peptides, proteins), membrane receptors for inhibition / modulation (GPCR, ion channels) and complex entities (Virus-like Particles, bacteria, whole cells). Nanofitin®-based drugs aim at overcoming antibodies’ limitations and outperforming current targeted therapies by allowing local delivery formulations, single-gene multi-specific molecules and Nanofitin®-Drug-Conjugates.

Meet us

PEGS Europe

PEGS Europe

Meet us at PEGS Europe
@ Lisbon, Portugal,
October 31 – November 4, 2016

Visit the event website

World Vaccine Congress 2016

World Vaccine Congress 2016

Meet us at World Vaccine Congress
@ Barcelona, Spain,
October 10-12, 2016

Visit the event website

Competitive Advantages

Nanofitin® Therapeutics

Partnering Strategy